Sigyn Therapeutics (OTCMKTS:SIGY – Get Free Report) and SI-BONE (NASDAQ:SIBN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
Risk and Volatility
Sigyn Therapeutics has a beta of -1.58, meaning that its stock price is 258% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Earnings and Valuation
This table compares Sigyn Therapeutics and SI-BONE’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sigyn Therapeutics||N/A||N/A||-$2.93 million||($0.09)||-3.56|
|SI-BONE||$106.41 million||8.23||-$61.26 million||($1.35)||-16.77|
This table compares Sigyn Therapeutics and SI-BONE’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Sigyn Therapeutics and SI-BONE, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SI-BONE has a consensus price target of $28.00, indicating a potential upside of 23.67%. Given SI-BONE’s higher probable upside, analysts clearly believe SI-BONE is more favorable than Sigyn Therapeutics.
SI-BONE beats Sigyn Therapeutics on 5 of the 9 factors compared between the two stocks.
About Sigyn Therapeutics
Sigyn Therapeutics, Inc. operates as a medical technology company, focuses on creating therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. It also developing ChemoPrep to enhance the tumor site delivery of chemotherapy; and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. The company is headquartered in San Diego, California.
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.